References
- Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12(6):520–527. doi:https://doi.org/10.1093/neuonc/nop066
- Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-oncology 2012;14(suppl 5):v1–v49. doi:https://doi.org/10.1093/neuonc/nos218
- Theeler BJ, Yung WA, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology 2012;79(18):1917–1926. doi:https://doi.org/10.1212/WNL.0b013e318271f7cb
- Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al.; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. doi:https://doi.org/10.1016/j.ccr.2009.12.020
- Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73. doi:https://doi.org/10.1016/j.ccr.2006.02.019
- Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302(3):261–75. doi:https://doi.org/10.1001/jama.2009.997
- Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, et al. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 2009;302(3):276–89. doi:https://doi.org/10.1001/jama.2009.1022
- Wood MD, Halfpenny AM, Moore SR. Applications of molecular neuro-oncology - A review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn Pathol. 2019;14(1):29. doi:https://doi.org/10.1186/s13000-019-0802-8
- Yang W, Warrington NM, Taylor SJ, Whitmire P, Carrasco E, Singleton KW, Wu N, Lathia JD, Berens ME, Kim AH, et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Transl Med. 2019;11(473):eaao5253. doi:https://doi.org/10.1126/scitranslmed.aao5253
- Hottinger AF, Khakoo Y. Update on the management of familial central nervous system tumor syndromes. Curr Neurol Neurosci Rep. 2007;7(3):200–207. doi:https://doi.org/10.1007/s11910-007-0031-5
- Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics. 2009;6(3):427–435. doi:https://doi.org/10.1016/j.nurt.2009.05.001
- Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre J-Y, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41(8):899–904. doi:https://doi.org/10.1038/ng.407
- Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, Wang SS, Bondy M, Houlston R, Jenkins RB, Wrensch M, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131(12):1877–1888. doi:https://doi.org/10.1007/s00439-012-1212-0
- Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544–1550. doi:https://doi.org/10.1093/jnci/djm170
- Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, et al.; Brain Tumor Epidemiology Consortium. Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113(7 Suppl):1953–1968. doi:https://doi.org/10.1002/cncr.23741
- Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Craft AW, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380(9840):499–505. doi:https://doi.org/10.1016/S0140-6736(12)60815-0
- Hardell L, Carlberg M, Mild KH. Use of mobile phones and cordless phones is associated with increased risk for glioma and acoustic neuroma. Pathophysiology 2013;20(2):85–110. doi:https://doi.org/10.1016/j.pathophys.2012.11.001
- Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013;310(17):1842–1850. doi:https://doi.org/10.1001/jama.2013.280319
- Volkman J. Sterols in microorganisms. Appl Microbiol Biotechnol. 2003;60(5):495–506. doi:https://doi.org/10.1007/s00253-002-1172-8
- De Stefani E, Boffetta P, Ronco AL, Brennan P, Deneo-Pellegrini H, Carzoglio JC, Mendilaharsu M. Plant sterols and risk of stomach cancer: a case-control study in Uruguay. Nutr Cancer 2000;37(2):140–144. doi:https://doi.org/10.1207/S15327914NC372_4
- Reddy B, Engle A, Katsifis S, Simi B, Bartram HP, Perrino P, Mahan C. Biochemical epidemiology of colon cancer: Effect of types of dietary fiber on fecal mutagens, acid, and neutral sterols in healthy subjects. Cancer Res. 1989;49(16):4629–4635.
- Gorin A, Gabitova L, Astsaturov I. Regulation of cholesterol biosynthesis and cancer signaling. Curr Opin Pharmacol. 2012;12(6):710–716. doi:https://doi.org/10.1016/j.coph.2012.06.011
- Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 2011;71(9):3236–3245. doi:https://doi.org/10.1158/0008-5472.CAN-10-3894
- Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell. 2010;17(4):348–361. doi:https://doi.org/10.1016/j.ccr.2010.01.022
- Delarue FL, Adnane J, Joshi B, Blaskovich MA, Wang D-A, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD, et al. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene 2007;26(5):633–640. doi:https://doi.org/10.1038/sj.onc.1209819
- Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 2009;106(14):5837–5841. doi:https://doi.org/10.1073/pnas.0812029106
- Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: New players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9(4):358–365. doi:https://doi.org/10.1097/01.mco.0000232894.28674.30
- Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7(10):763–777. doi:https://doi.org/10.1038/nrc2222
- Zhang B, Wu J, Guo P, Wang Y, Fang Z, Tian J, Yu Y, Teng W, Luo Y, Li Y, et al. Down-regulation of SREBP via PI3K/AKT/mTOR pathway inhibits the proliferation and invasion of non-small-cell lung cancer cells. Onco Targets Ther. 2020;13:8951–8961. doi:https://doi.org/10.2147/OTT.S266073
- Oliveras G, Blancafort A, Urruticoechea A, Campuzano O, Gómez-Cabello D, Brugada R, López-Rodríguez ML, Colomer R, Puig T. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer. Ann NY Acad Sci. 2010;1210(1):86–92. doi:https://doi.org/10.1111/j.1749-6632.2010.05777.x
- Bhatia B, Hsieh M, Kenney AM, Nahlé Z. Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma. Oncogene 2011;30(4):410–422. doi:https://doi.org/10.1038/onc.2010.454
- Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, Milstien S, Zhou H, Spiegel S, et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res. 2012;72(3):726–735. doi:https://doi.org/10.1158/0008-5472.CAN-11-2167
- Uddin S, Hussain AR, Ahmed M, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, et al. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol. 2009;104(7):1790–1801. doi:https://doi.org/10.1038/ajg.2009.230
- Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009;100(9):1369–1372. doi:https://doi.org/10.1038/sj.bjc.6605007
- Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 2008;8(6):512–521. doi:https://doi.org/10.1016/j.cmet.2008.10.008
- Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009;325(5936):100–104. doi:https://doi.org/10.1126/science.1168974
- Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018;14(8):452–463. doi:https://doi.org/10.1038/s41574-018-0037-x
- Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer 2016;16(11):718–731. doi:https://doi.org/10.1038/nrc.2016.76
- Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148(1–2):244–258. doi:https://doi.org/10.1016/j.cell.2011.12.017
- Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY-J, Watson AD, Phelps M, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 2009;106(31):12932–12937. doi:https://doi.org/10.1073/pnas.0906606106
- Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011;1(5):442–456. doi:https://doi.org/10.1158/2159-8290.CD-11-0102
- Khaidakov M, Mitra S, Kang B-Y, Wang X, Kadlubar S, Novelli G, Raj V, Winters M, Carter WC, Mehta JL, et al. Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer. PLoS One 2011;6(5):e20277. doi:https://doi.org/10.1371/journal.pone.0020277
- Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896. doi:https://doi.org/10.1016/j.ctrv.2019.101896
- Dai Z, Wang L, Wang X, Zhao B, Zhao W, Bhardwaj SS, Ye J, Yin Z, Zhang J, Zhao S, et al. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3. Oncol Rep. 2018;40(2):867–876. doi:https://doi.org/10.3892/or.2018.6512
- Lian G, Chen S, Ouyang M, Li F, Chen L, Yang J. Colon cancer cell secretes EGF to promote M2 polarization of TAM through EGFR/PI3K/AKT/mTOR pathway. Technol Cancer Res Treat. 2019;18:1533033819849068. doi:https://doi.org/10.1177/1533033819849068
- Sun Z, Xue H, Wei Y, Wang C, Yu R, Wang C, Wang S, Xu J, Qian M, Meng Q, et al. Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis. Clin Sci (Lond). 2019;133(10):1167–1184. doi:https://doi.org/10.1042/CS20190145
- Wang X, Zeng J, Wang L, Zhang X, Liu Z, Zhang H, Dong J. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway. Oncol Rep. 2017;38(1):141–150. doi:https://doi.org/10.3892/or.2017.5699
- Wong K-K, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20(1):87–90. doi:https://doi.org/10.1016/j.gde.2009.11.002
- Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061.
- Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807–1812. doi:https://doi.org/10.1126/science.1164382
- Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22(10):1926–1933. doi:https://doi.org/10.1200/JCO.2004.07.193
- Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159(1):359–367. doi:https://doi.org/10.1016/S0002-9440(10)61702-6
- Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines . Brain Pathol. 1999;9(3):469–479. doi:https://doi.org/10.1111/j.1750-3639.1999.tb00536.x
- Mao H, LeBrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012;30(1):48–56. doi:https://doi.org/10.3109/07357907.2011.630050
- Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318(5848):287–290. doi:https://doi.org/10.1126/science.1142946
- Xue L, Qi H, Zhang H, Ding L, Huang Q, Zhao D, Wu BJ, Li X. Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy. Front Oncol. 2020;10(1510):1510. doi:https://doi.org/10.3389/fonc.2020.01510
- Huang PH, Cavenee WK, Furnari FB, White FM. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle. 2007;6(22):2750–2754. doi:https://doi.org/10.4161/cc.6.22.4922
- Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010;10(5):319–331. doi:https://doi.org/10.1038/nrc2818
- Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387(6630):296–269. doi:https://doi.org/10.1038/387296a0
- Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y, et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007;12(4):355–366. doi:https://doi.org/10.1016/j.ccr.2007.09.007
- Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS, Collins VP. Refined mapping of 12q13–q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. 1996;56(22):5141–5145.
- Riemenschneider MJ, Büschges R, Wolter M, Reifenberger J, Boström J, Kraus JA, Schlegel U, Reifenberger G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999;59(24):6091–6096.
- Rao SK, Edwards J, Joshi AD, Siu I-M, Riggins GJ. A survey of glioblastoma genomic amplifications and deletions. J Neurooncol. 2010;96(2):169–179. doi:https://doi.org/10.1007/s11060-009-9959-4
- Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D. Tumor‐infiltrating dendritic cells in adenocarcinomas of the breast: A study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 1999;84(3):309–314. doi:https://doi.org/10.1002/(SICI)1097-0215(19990621)84:3<309::AID-IJC19>3.0.CO;2-3
- Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19(33):3816–3822. doi:https://doi.org/10.1038/sj.onc.1203700
- Marlow MM, Shah SS, Véliz EA, Ivan ME, Graham RM. Treatment of adult and pediatric high-grade gliomas with Withaferin A: antitumor mechanisms and future perspectives. J Nat Med. 2017;71(1):16–26. doi:https://doi.org/10.1007/s11418-016-1020-2
- Larsson O. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol. 1996;22(3):197–212. doi:https://doi.org/10.1016/1040-8428(96)00193-X
- Yamauchi Y, Iwamoto N, Rogers MA, Abe-Dohmae S, Fujimoto T, Chang CCY, Ishigami M, Kishimoto T, Kobayashi T, Ueda K, et al. Deficiency in the lipid exporter ABCA1 impairs retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum. J Biol Chem. 2015;290(39):23464–23477. doi:https://doi.org/10.1074/jbc.M115.662668
- Moon S-H, Huang C-H, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell 2019;176(3):564–80.e19. doi:https://doi.org/10.1016/j.cell.2018.11.011
- Wei S, Liu L, Chen Z, Yin W, Liu Y, Ouyang Q, Zeng F, Nie Y, Chen T. Artesunate inhibits the mevalonate pathway and promotes glioma cell senescence. J Cell Mol Med. 2020;24(1):276–284. doi:https://doi.org/10.1111/jcmm.14717
- Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21(13):2508–2518. doi:https://doi.org/10.1200/JCO.2003.21.13.2508
- Guzman F, Fazeli Y, Khuu M, Salcido K, Singh S, Benavente CA. Retinoblastoma tumor suppressor protein roles in epigenetic regulation. Cancers 2020;12(10):2807. doi:https://doi.org/10.3390/cancers12102807
- Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu HJ, Benedict WF, Yandell DW, Louis DN. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol. 1994;36(5):714–721. doi:https://doi.org/10.1002/ana.410360505
- Tortosa A, Ino Y, Odell N, Swilley S, Sasaki H, Louis DN, Henson JW. Molecular genetics of radiographically defined de novo glioblastoma multiforme. Neuropathol Appl Neurobiol. 2000;26(6):544–552. doi:https://doi.org/10.1046/j.0305-1846.2000.00290.x
- Bahuau M, Vidaud D, Jenkins RB, Bièche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res. 1998;58(11):2298–2303.
- Topacio BR, Zatulovskiy E, Cristea S, Xie S, Tambo CS, Rubin SM, Sage J, Kõivomägi M, Skotheim JM. Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein’s C-terminal helix. Mol Cell. 2019;74(4):758–70.e4. doi:https://doi.org/10.1016/j.molcel.2019.03.020
- Yp Lam EdT H-K, Ng JCS, Pang MF, Roussel NM, Hjelm P. Expression of p19 INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg. 2000;14(1):28–32.
- Kitajima S, Li F, Takahashi C. Tumor milieu controlled by RB tumor suppressor. IJMS. 2020;21(7):2450. doi:https://doi.org/10.3390/ijms21072450
- Jeon T-I, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab. 2012;23(2):65–72. doi:https://doi.org/10.1016/j.tem.2011.10.004
- Shamma A, Takegami Y, Miki T, Kitajima S, Noda M, Obara T, Okamoto T, Takahashi C. Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell. 2009;15(4):255–269. doi:https://doi.org/10.1016/j.ccr.2009.03.001
- Takahashi C, Sasaki N, Kitajima S. Twists in views on RB functions in cellular signaling, metabolism and stem cells. Cancer Sci. 2012;103(7):1182–1188. doi:https://doi.org/10.1111/j.1349-7006.2012.02284.x
- Facchini G, Ignarro RS, Rodrigues-Silva E, Vieira AS, Lopes-Cendes I, Castilho RF, Rogerio F. Toxic effects of phytol and retinol on human glioblastoma cells are associated with modulation of cholesterol and fatty acid biosynthetic pathways. J Neurooncol. 2018;136(3):435–443. doi:https://doi.org/10.1007/s11060-017-2672-9
- Kosti A, de Araujo PR, Li W-Q, Guardia GDA, Chiou J, Yi C, Ray D, Meliso F, Li Y-M, Delambre T, et al. The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation. Genome Biol. 2020;21(1):195. doi:https://doi.org/10.1186/s13059-020-02115-y
- Ahmad F, Sun Q, Patel D, Stommel JM. Cholesterol metabolism: A potential therapeutic target in glioblastoma. Cancers 2019;11(2):146. doi:https://doi.org/10.3390/cancers11020146
- Parrales A, Thoenen E, Iwakuma T. The interplay between mutant p53 and the mevalonate pathway. Cell Death Differ. 2018;25(3):460–470. doi:https://doi.org/10.1038/s41418-017-0026-y